RAPP vs TFX · rev $20.0M vs P/E 2083, rev $1.12B
Rapport Therapeutics, Inc. Common Stock (RAPP) versus Teleflex Incorporated (TFX) — a side-by-side from cached financials, not a winner call.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
Teleflex Incorporated (TFX) is a medical instruments & supplies company listed on NYSE.
Latest reported RAPP revenue for 2026-06-30 was $20.0M. Net income was -$76.5M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. RAPP currently screens at market cap $532.9M.
Latest reported TFX revenue for 2026-06-30 was $1.12B. Net income was $91.5M. TFX currently screens at market cap $5.53B and trailing P/E 2082.7.
RAPP currently screens at market cap $532.9M. TFX currently screens at market cap $5.53B and trailing P/E 2082.7.
Not investment advice. Open the RAPP and TFX stock pages for the full models.
Not investment advice.